ReviewHuman vaccines & immunotherapeutics2015
The value of childhood combination vaccines: From beliefs to evidence.
Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 146 citations in OpenAlex.
- Co-administration of Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.Human vaccines & immunotherapeutics · 2020Trial
- Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.Human vaccines & immunotherapeutics · 2019Trial
- Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.Human vaccines & immunotherapeutics · 2017Trial
- Economic implications of switching to the hexavalent infant vaccine in an immunization program in India.Human vaccines & immunotherapeutics · 2026Article
- Costs of managing adverse reactions to hexavalent vaccines: Comparison of DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib in France and Spain.Human vaccines & immunotherapeutics · 2026Article
- A Global Perspective of Childhood Vaccinations: Past, Present, and Future-From Smallpox to mRNA.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- Public trust and evidence: decisions on vaccines must be anchored in science.The Lancet regional health. Europe · 2026Article
- Article
- Article
- Measles-Containing Vaccine Use for Children Aged 12 to 47 Months, 2015 to 2025.JAMA network open · 2026Article
- Article
- Global vaccine development.Nature medicine · 2026Review
- Review
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- Alternative Childhood Vaccination Schedules in Israel: A Mixed-Methods Study on Prevalence, Patterns, and Public Health Implications.Vaccines · 2026Article
- Reporting profile of adverse events following DTaP-IPV/Hib pentavalent vaccine: A 13-year real-world surveillance data analysis.Human vaccines & immunotherapeutics · 2025Article
- Service delivery costs of vaccination at health facilities in Guangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- The associations between childhood vaccine history and COVID-19 vaccine uptake among older adults in 28 high-income countries.Research square · 2025Article
- An Evaluation of the Safety, Immunogenicity, and Protective Efficacy of a Combined Diphtheria-Tetanus-Acellular Pertussis,Vaccines · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although vaccination is one of the most cost-effective health care interventions, under-vaccination and variation in coverage rates lower than policy targets is rising in developed countries, partly due to concerns about vaccination value and benefits. By merging various antigens into a single product, combination vaccines represent a valuable tool to mitigate the burden associated with the numerous injections needed to protect against vaccine preventable infectious diseases and increase coverage rate, possibly through various behavioral mechanisms which have yet to be fully explored. Beyond their cost-effectiveness in protecting against more diseases with fewer injections, combination vaccines also have several other benefits, for children, their parents/carers, as well as for the health system and the population as a whole. The objectives of this review are to identify and illustrate the value of combination vaccines for childhood immunization. Evidence was classified into 2 groups: benefits for society and benefits for public health and healthcare systems. This article also highlights the value of innovation and challenges of combination vaccine development as well as the need for an increased number of suppliers to mitigate the impact of any potential vaccine shortage. Increasing public confidence in vaccines and combination vaccines is also critical to fully exploit their benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.